Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price (NYSE:BMY)
· seekingalpha.com
Bristol Myers Squibb's growth portfolio now drives nearly 60% of revenue, offsetting legacy drug declines and supporting total revenue growth. See why BMY stock is a Buy.
iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity f...